Journal Information
Vol. 45. Issue 10.
Pages 502-507 (October 2009)
Share
Share
Download PDF
More article options
Vol. 45. Issue 10.
Pages 502-507 (October 2009)
Original articles
Full text access
Lung Cancer and COPD: a Common Combination
Cáncer de pulmón y EPOC: una asociación frecuente
Visits
5221
José Abal Arcaa,
Corresponding author
jose.abal.arca@sergas.es

Corresponding author.
, Isaura Parente Lamelasa, Raquel Almazán Ortegab, José Blanco Péreza, María Elena Toubes Navarroa, Pedro Marcos Velázqueza
a Pneumology Department. Hospital Complex of Ourense, Ourense, Spain
b Research Unit. Hospital Complex of Ourense, Ourense, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract
Background and objective

To analyse frequency, characteristics and patient survival with lung cancer (LC) and Common Obstructive Pulmonary Disease (COPD), comparing them with patients that do not have COPD.

Material and methods

A retrospective study, of patients diagnosed by means of cytohistology. Survival was estimated by the Kaplan-Meier method. Statistical analysis was carried out using SPSS 15.0.

Results

A total of 996 patients were diagnosed, 39.8% with COPD. Mean age70±9.19 years. GOLD stages: I 18.2%, II 53.6%, III 24%, IV 4.2%. The histological types: squamous cell carcinoma 48.2%, adenocarcinoma 22%, and small cell carcinoma 22.5%. Survival was longer in the COPD group.

Conclusions

LC and COPD are combined in 39.8%. Squamous cell type is more frequent and survival was longer in the COPD group.

Keywords:
Lung cancer
COPD
Epidemiology
Survival
Resumen
Introducción y objetivo

Analizar la frecuencia, las características y la supervivencia de los pacientes con cáncer de pulmón (CP) y enfermedad pulmonar obstructiva crónica (EPOC), comparándolas con las de pacientes sin EPOC.

Material y métodos

Se ha realizado un estudio retrospectivo de pacientes diagnosticados de CP mediante citohistología. Se estimó la supervivencia por el método de Kaplan-Meier. El análisis estadístico se realizó con el programa SPSS 15.0.

Resultados

Se diagnosticó de CP a 996 pacientes, el 39,8% con EPOC. La edad media (± desviación estándar) de estos últimos era de 70 ± 9,19 años. En cuanto a los estadios GOLD, el 18,2% se encontraba en estadio I, el 53,6% en estadio II, el 24% en estadio III y el 4,2% en estadio IV. Según la citohistología, el 48,2% de los CP eran escamosos, el 22% adenocarcinomas y el 22,5% microcíticos. La supervivencia fue mayor en el grupo con EPOC.

Conclusiones

El CP y la EPOC se asocian en un 39,8% de los casos. La estirpe más frecuente del CP es la escamosa y la supervivencia es mayor en el grupo con EPOC.

Palabras clave:
Cáncer de pulmón
EPOC
Epidemiología
Supervivencia
Full text is only aviable in PDF
References
[1.]
J.A. Ahmedin, R.C. Tiwari, T. Murray.
Cancer statistics.
CA Cancer J Clin, 54 (2004), pp. 8-29
[2.]
G. López-Abente, M. Pollán, N. Aragoneses, B. Pérez, V. Hernández, V. Lope, et al.
Situación del cáncer en España: incidencia.
Anales Sis San Navarra, 27 (2004), pp. 165-173
[3.]
R.A. Pauwels, A.S. Buist, P.M. Calverley, C.R. Jenkins, S.S. Hurd, GOLD Scientific Committee.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[4.]
G. Peces-Barba, J.A. Barberá, A. Agustí, C. Casanova, A. Casas, J.L. Izquierdo, et al.
Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC.
Arch Bronconeumol, 44 (2008), pp. 271-281
[5.]
V. Sobradillo, M. Miravitlles, R. Gabriel, C.A. Jiménez, C. Villasante, J.L. Viejo, et al.
Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study.
Chest, 118 (2000), pp. 981-989
[6.]
P. Bach, R.J. Ginsberg.
Epidemiology of lung cancer.
Lung Cancer, pp. 1-10
[7.]
E. Barreiro.
EPOC y cáncer de pulmón.
Arch Bronconeumol×, 44 (2008), pp. 399-401
[8.]
D.M. Skillrud, K.P. Oxford, R.D. Millar.
Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study.
Ann Intern Med, 105 (1986), pp. 503-507
[9.]
D.M. Mannino, S.M. Aguayo, T.L. Petty, S.C. Redd.
Low lung function and incident lung cancer in the United States: data from First National Health and Nutrition Examination Survey follow-up.
Arch Intern Med, 163 (2003), pp. 1475-1480
[10.]
A. Nomura, G.N. Stemmermann, P.H. Chyou, E.B. Marcus, S. Buist.
Prospective study of pulmonary function and lung cancer.
Am Rev Respir Dis, 144 (1991), pp. 307-311
[11.]
N.R. Anthonisen, J.E. Connett, J.P. Kiley, M.D. Altose, W.C. Bailey, A.S. Buist, et al.
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study.
JAMA, 272 (1994), pp. 1497-1505
[12.]
A. Papi, G. Casoni, G. Caramori, I. Guzzinati, P. Boschetto, F. Ravenna, et al.
COPD increases the risk of squamous subtype in smokers who develop non-small cell lung carcinoma.
Thorax, 59 (2004), pp. 679-681
[13.]
L.H. Kuller, J. Ockene, E. Meilahn, K.H. Svendsen.
Relation of forced expiratory volume in one second (FEV1) to lung cancer mortality in the multiple risk factor intervention trial (MRFIT).
Am J Epidemiol, 132 (1990), pp. 265-274
[14.]
M.S. Tockman, N.R. Anthonisen, E.C. Wrigh, M.G. Donithan.
Airways obstruction and the risk for lung cancer.
Ann Intern Med, 106 (1987), pp. 512-518
[15.]
B.H. Cohen, E.L. Diamond, C.G. Graves, P. Kreiss, D.A. Levy, H.A. Menkes, et al.
A common familial component in lung cancer and chronic obstructive pulmonary disease.
Lancet, 2 (1977), pp. 523-536
[16.]
E. Brambilla, W.D. Travis, T.V. Colby, B. Corrin, Y. Shimosato.
The new World Health Organization classification of lung tumours.
Eur Respir J, 18 (2001), pp. 1059-1068
[17.]
C.F. Mountain.
Revisions in the International System for Staging Lung Cancer.
Chest, 111 (1997), pp. 1710-1717
[18.]
D.D. Sin, N.R. Anthonisen, J.B. Soriano, A.G.N. Agustí.
Mortality in COPD: role of comorbidities.
Eur Respir J, 28 (2006), pp. 1245-1257
[19.]
N.R. Anthonisen, M.A. Skeans, R.A. Wise, J. Manfreda, R.E. Kanner, J.E. Connett.
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Ann Intern Med, 142 (2005), pp. 233-239
[20.]
C. Montero, M. Rosales, I. Otero, M. Blanco, G. Rodríguez, S. Peterga, et al.
Cáncer de pulmón en el Área Sanitaria de A Coruña: incidencia, abordaje clínico y supervivencia.
Arch Bronconeumol, 39 (2003), pp. 209-216
[21.]
L.E. Eberly, J. Ockene, R. Sherwin, L. Yang, C. Kuller.
Pulmonary function as a predictor of lung cancer mortality in continuing cigarette smokers and in quitters.
Int J Epidemiol, 32 (2003), pp. 592-599
[22.]
M.P. Purdue, L. Gold, B. Järvholm, M.C.R. Alavanja, M.H. Ward, R. Vermeulen.
Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers.
Thorax, 62 (2007), pp. 51-56
[23.]
S. Wasswa-Kintu, W.Q. Gan, S.F.P. Man, P.D. Pare, D.D. Din.
Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis.
Thorax, 60 (2005), pp. 570-575
[24.]
J.L. Izquierdo.
Nuevos parámetros clínicos en la EPOC.
Arch Bronconeumol, 44 (2008), pp. 4-10
[25.]
M.J. Santos-Martínez, V. Curull, M.L. Blanco, F. Macià, S. Mojal, J. Vila, et al.
Características del cáncer de pulmón en un hospital universitario. Cambios epidemiológicos e histológicos en relación con una serie histórica.
Arch Bronconeumol, 41 (2005), pp. 307-312
[26.]
S.Y. Wang, Y.L. Hu, Y.L. Wu, X. Li, G.B. Chi, Y. Chen, et al.
A comparative study of the risk factors for lung cancer in Guangdong.
China. Lung Cancer, 14 (1996), pp. S99-S105
[27.]
L. Miravet, A. Paradís, S. Peláez, M. Arnal, F. Cabadés.
Evolución del carcinoma broncopulmonar en el norte de la provincia de Castellón, 1993-2002.
Arch Bronconeumol, 40 (2004), pp. 553-557
[28.]
J. Sánchez de Cos, C. Disdier, J. Corral, J.A. Riesco, M.A. Sojo, J.F. Masa.
Supervivencia global a largo plazo en el cáncer de pulmón. Análisis de una serie de 610 pacientes no seleccionados.
Arch Bronconeumol, 40 (2004), pp. 268-274
[29.]
Nacional Cancer Institute. SEER. Cancer Statistics Review 1975–2001, Bethesda, 2005, Disponible en, http://www.statecancerprofiles.cancer.gov
[30.]
A. López-Encuentra, Bronchogenic Co-operative Group.
Comorbidity in operable lung cancer:a multicenter descriptive study on 2992 patients.
Lung Cancer, 35 (2002), pp. 263-269
[31.]
Y. Sekine, M. Behnia, T. Fujisawa.
Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC.
Lung Cancer, 37 (2002), pp. 95-101
[32.]
Grupo Cooperativo de Carcinoma.
Broncogénico de SEPAR (GCCB-S). Cirugía del carcinoma broncogénico en España. Estudio descriptivo.
Arch Bronconeumol, 31 (1995), pp. 303-309
[33.]
G. Gómez, R. Güell, A. González, J.J. Fibla, G. Estrada, C. León.
Influencia de un programa de rescate en la decisión quirúrgica en pacientes con carcinoma broncogénico y EPOC.
Arch Bronconeumol, 43 (2007), pp. 262-266
[34.]
A. López-Encuentra, J. Astudillo, J. Cerezal, F. González-Aragoneses, N. Novoa, A. Sánchez-Palencia.
Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Prognostic value of chronic obstructive pulmonary disease in 2,994 cases of lung cancer.
Eur J Cardiothorac Surg, 27 (2005), pp. 8-13
[35.]
R.J. Battafarano, J.F. Piccirillo, B.F. Meyers, H.S. Hsu, T.J. Guthrie, J.D. Cooper, et al.
Impact of comorbidity on survival after surgical resection in patients with stage I nonsmall cell lung cancer.
J Thorac Cardiovasc Surg, 123 (2002), pp. 280-287
Copyright © 2009. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?